The effect of inositol administration on CRP levels and the pregnancy rate of polycystic ovary syndrom (pcos) pations

Investigating the effect of inositol administration on CRP levels and the pregnancy rate of polycystic ovary syndrom (pcos) pations candidates for freezed embryo transfer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230522058253N6

Enrollment

206

Registered

2025-04-18

Start date

2025-04-14

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Increasing successful pregnancy and reducing CRP levels with inositol in women with polycystic ovary syndrome. Female infertility of uterine origin

Interventions

Intervention 1: Intervention group: In this group, metformin will be prescribed at least 1000 mg for two months before embryo transfer, and inositol will also be prescribed in addition to metformin.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women with PCOS (Rotterdam criteria) are candidates for IVF Age 18-40 years No underlying or chronic disease Female infertility factor Patients have not received drugs affecting CRP, such as inositol, for 2 months before the start of the cycle

Exclusion criteria

Exclusion criteria: Severe endometriosis Any type of acute or chronic illness that affects CRP levels Hydrosalpinx Drug allergies

Design outcomes

Primary

Measure	Time frame
Pregnancy outcome success rate in polycystic ovary syndrome patients who are candidates for frozen embryo transfer using inositol. Timepoint: A maternal blood sample will be taken 12-16 days after intrauterine insemination to check for beta HCG to check for pregnancy. Finally, pregnancy is confirmed based on clinical level measurements by the presence of a gestational sac on sonography at the fourth week. Pregnancy and success rates of intrauterine insemination in both groups are then compared. Method of measurement: Chemical pregnancy assessment with beta HCG check on days 12-16 after intervention and clinical pregnancy measurement by the presence of gestational sac on sonography at 4th week.;Average CRP reduction in polycystic ovary syndrome patients who are candidates for frozen embryo transfer using inositol. Timepoint: Once before starting treatment and once on the day of embryo transfer. Method of measurement: CRP levels will be measured once before starting treatment with metformin and inositol. The patient will receive the drugs for 8 weeks. Then, on the day of the transfusion, CRP will be checked again, and the result on the day of the transfusion will be compared with the previous CRP result.	—

Measure

Time frame

Pregnancy outcome success rate in polycystic ovary syndrome patients who are candidates for frozen embryo transfer using inositol. Timepoint: A maternal blood sample will be taken 12-16 days after intrauterine insemination to check for beta HCG to check for pregnancy. Finally, pregnancy is confirmed based on clinical level measurements by the presence of a gestational sac on sonography at the fourth week. Pregnancy and success rates of intrauterine insemination in both groups are then compared. Method of measurement: Chemical pregnancy assessment with beta HCG check on days 12-16 after intervention and clinical pregnancy measurement by the presence of gestational sac on sonography at 4th week.;Average CRP reduction in polycystic ovary syndrome patients who are candidates for frozen embryo transfer using inositol. Timepoint: Once before starting treatment and once on the day of embryo transfer. Method of measurement: CRP levels will be measured once before starting treatment with metformin and inositol. The patient will receive the drugs for 8 weeks. Then, on the day of the transfusion, CRP will be checked again, and the result on the day of the transfusion will be compared with the previous CRP result.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSHamim Pilehvari

Hamedan University of Medical Sciences

sh.pilehvari@yahoo.com0098813832012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026